Iikura Y, Aoyama T, Hiraide M, Wakatsuki T, Nakayama I, Ogura M, Ooki A, Takahari D, Chin K, Yamaguchi K, Hama T. Safety evaluation of fixed-dose nivolumab in patients with gastric cancer.
Health Sci Rep 2022;
5:e673. [PMID:
35662976 PMCID:
PMC9165198 DOI:
10.1002/hsr2.673]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2021] [Revised: 04/20/2022] [Accepted: 05/08/2022] [Indexed: 01/05/2023] Open
Abstract
Background and Aims
This study aimed to examine the safety of fixed‐dose nivolumab.
Methods
We retrospectively reviewed the medical records of 113 Japanese patients with gastric cancer who were previously treated with cytotoxic chemotherapy and initiated nivolumab. The endpoints were the incidence of Grade 2 or higher immune‐related adverse events (irAEs) in the conventional dose (3 mg/kg) and fixed‐dose groups (240 mg).
Results
The incidence rates of irAEs in the conventional‐dose and fixed‐dose groups were 29.9% and 19.4%, respectively, and the rates of Grade 2 or higher irAEs were 23.3% and 19.4%, respectively, with no significant difference between the two groups, suggesting that nivolumab at 240 mg is as safe as the 3 mg/kg dose.
Conclusion
This is the first report on the safety of nivolumab at 240 mg in Japanese patients.
Collapse